SEC For	m 4 FORM	Δ						юті			EXCHA		COM						
		20 31	~ 1 🗠	0 JL			LJ A					10		0	ОМВ	APPRO\	/AL		
Check Section obligat Instruc	led pur	NT OF CHANGES IN BENEFICIAL OWNERSHIP										OMB Number: 3235-0287   Estimated average burden    hours per response: 0.5							
1. Name and Address of Reporting Person <sup>*</sup> Legault Pierre															tionship c all applic Directo	able)	g Pers	ion(s) to Issu 10% Ow	
(Last) (First) (Middle) C/O SYNDAX PHARMACEUTICALS, INC.					12	3. Date of Earliest Transaction (Month/Day/Year) 12/20/2021									Officer (give title Other (specify below) below)				
35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3														6. Individual or Joint/Group Filing (Check Applica Line)				olicable	
(Street) WALTHAM MA 02451														X		led by Mor	ed by One Reporting Person ed by More than One Reporting		
(City) (State) (Zip)																			
		Tab	ole I - I	Non-Deri	vativ	e Sec	curit	ties A	cquire	ed, D	isposed o	of, or B	enefici	ally	Owned				
1. Title of Security (Instr. 3)				2. Transaction Date (Month/Day/Y		Execution Date,		Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 at			Benefici Owned F		es ally Following	Form (D) o	r Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) or (D)	Price		Reporte Transact (Instr. 3	tion(s)		°	(Instr. 4)
Common Stock				12/20/2021				М		20,000	A	\$7.0	8 36,		,000		D		
Common Stock				12/20/2021				<b>S</b> <sup>(1)</sup>		20,000	D	\$21.01	)125 <sup>(2)</sup> 16,		,000	0 D			
Common Stock				12/22/2021				М		24,000	A	\$7.8	\$7.88		0,000		D		
Common Stock				12/22/2021				<b>S</b> <sup>(1)</sup>		24,000	D	\$22.00	22.0086 <sup>(3)</sup>		6,000		D		
		-	Table								sposed of, , converti				wned		,		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transa Code ( 8)	action	5. Number tion of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amoun of Securities Underlying Derivative Securit (Instr. 3 and 4)		int 8. Di Si	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownershi (Instr. 4)
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amou or Numb of Share	er					
Stock Options (Right to buy)	\$7.08	12/20/2021		Ν				20,000	(	4)	01/04/2027	Commor Stock	<sup>1</sup> 20,00	00	\$0.00	0.00		D	
Stock Options (Right to buy)	\$7.88	12/22/2021			Μ			24,000	(	4)	06/10/2029	Common Stock	<sup>1</sup> 24,00	00	\$0.00	0.00		D	

## Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 63,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested.

2. The sale prices ranged from \$21.00 to \$21.0238.

3. The sale prices ranged from \$22.00 to \$22.02.

4. This option is fully vested.

Remarks:

<u>/s/ Michael A. Metzger, as</u> <u>Attorney-in-Fact</u>

12/22/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.